New York Menlo Park Washington DC London Paris | Madrid Tokyo Beijing Hong Kong |
Davis Polk & Wardwell LLP 99 Gresham Street London EC2V 7NG | 020 7418 1376 tel 020 7710 4893 fax jeffrey.obrien@davispolk.com |
| July 18, 2011 | |
Form 20-F for Fiscal Year Ended December 31, 2010 Filed February 14, 2011 Form 6-K Filed February 14, 2011 File Number: 333-82318 | |
Mr. Frank Wyman
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Dear Mr. Wyman:
I am writing on behalf of Novo Nordisk A/S (the “Company”) in connection with the Staff’s review of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2010. As we discussed on the telephone, I confirm that the Company has received and is considering its response to your letter dated July 14, 2011.
In order to ensure the completeness and accuracy of the Company’s response, it will be conducting a detailed review of the items concerned in respect of the above filing.
The Company anticipates being able to complete this review and provide a response to the SEC by Thursday, August 4.
Very truly yours,
/s/ Jeffrey R. O’Brien
Jeffrey R. O’Brien
Via Edgar Submission
A New York limited liability partnership. The principal place of business of the partnership in Great Britain
is the address set forth above at which a list of the partners' names is open for inspection.